lirilumab

Ligand id: 9310

Name: lirilumab

Classification
Compound class Antibody
International Nonproprietary Names
INN number INN
9415 lirilumab
Synonyms
1-7F9
BMS-986015
IPH2102
Database Links
Specialist databases
IMGT/mAb-DB 423
Other databases
Search PubMed clinical trials lirilumab
Search PubMed titles lirilumab
Search PubMed titles/abstracts lirilumab
Comments
Lirilumab (BMS-986015) is a fully human monoclonal antibody (mAb) which targets the KIRD2 subgroup of killer cell immunoglobulin like receptors (KIRs) on natural killer cells [1], being developed as an immuno-oncology clinical candidate. Identified targets include KIR2DL1, KIR2DL2, KIR2DL3, KIR2DS1 and KIR2DS2. Genes of KIR proteins are listed in HGNC family Killer cell immunoglobulin like receptors (KIR). ia an IgG4 isotype antibody considered suitable for a blocking , non-depleting mAb with clinical utility.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.